Figure 6. Effect of various therapies on the development of chronic allograft vasculopathy. Representative sections of mouse cardiac grafts at more than 100 days posttransplant from the following treatment groups (n = 4–8/group): (A) sMR1 (Verhoeff’s elastin stain, vessel score = 2.53 ± 1.94); (B) sMR1 (Masson’s trichrome stain); (C) sMR1 plus rapamycin (Verhoeff’s elastin stain, vessel score = 1.25 ± 1.25); (D) sMR1 plus rapamycin (Masson’s trichrome stain); (E) mMR1 (Verhoeff’s elastin stain, vessel score = 0.81 ± 0.53); (F) mMR1 plus late (day 30–33) cyclosporine (Verhoeff’s elastin stain, vessel score = 3.05 ± 0.69); (G) CTLA4Ig (Verhoeff’s elastin stain, vessel score 0.7 ± 0.41); (H) control isograft (Verhoeff’s elastin stain; vessel score = 0). Vessel scores are given as mean ± SEM. Original magnification ×200.